Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial.
Jessica M Moon, Kayla M Ratliff, Anthony M Hagele...
https://pubmed.ncbi.nlm.nih.gov/35010998/Actively Recruiting
Led by Nanjing Nutrabuilding Bio-tech Co., Ltd. · Updated on 2025-10-07
54
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating the effects of Dihydroberberine DHB supplementation in adults with pre-diabetes. The study aims to find out if DHB increases the blood levels of GLP-1, a hormone involved in blood sugar control, and how it affects appetite, mood, energy, body weight, blood sugar, and insulin. Participants will be compared to a placebo group to see if DHB has any measurable impact. Participants will take either DHB or a placebo daily for 6 weeks. The DHB group will receive four 100 mg capsules each day, totaling 400 mg daily, while the placebo group will receive four capsules containing an inactive substance. The study includes several visits during which blood and other markers related to GLP-1, glucose, and insulin will be tested after a single dose and after 6 weeks of supplementation. During the study, participants will wear continuous glucose monitors CGMs to track blood sugar levels and spend time in healthy glucose ranges. They will also rate their appetite, mood, and energy using visual scales. Researchers will assess changes in GLP-1 levels, blood sugar control, insulin resistance, and subjective feelings related to appetite and mood. The total study duration for each participant is about 6 weeks, with various laboratory tests, glucose monitoring, and questionnaires completed during this time.
CONDITIONS
Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes
K
Kotryna Dzekcioriute
E
Elizabeth Antoo, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nanjing Nutrabuilding Bio-tech Co., Ltd.
Lead Sponsor
Biofortis, Merieux NutriSciences
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Dihydroberberine (DHB) | Placebo |
|---|---|---|
| What is it? | Dihydroberberine (DHB) is a dietary supplement derived from berberine, formulated for oral use. Participants in this arm receive 400 mg daily (4 capsules of 100 mg each) for 6 weeks. | Participants receive 400 mg of placebo daily (4 capsules containing microcrystalline cellulose) for 6 weeks. Placebo capsules are designed to mimic the DHB capsules. |
| Role in the trial | Active experimental arm; oral DHB is being evaluated for effects on GLP-1, glycemic control, appetite, and mood in people with prediabetes. | Control arm; placebo capsules are used to mask treatment and isolate the effects of DHB. |
| Primary use | Investigational use in prediabetes, intended to assess effects on GLP-1 hormone levels, glycemic measures, appetite, and mood. Not established for routine treatment of prediabetes. | Inactive control; does not alter GLP-1, glycemic measures, appetite, or mood. Used to compare DHB effects in placebo-controlled fashion. |
| How is it given or performed? | Oral capsules, 400 mg total daily dose, taken once daily for 6 weeks. Participants must also use continuous glucose monitoring and diet-tracking apps. | Oral capsules, 400 mg daily, taken once daily for 6 weeks. Participants follow the same monitoring and tracking procedures as DHB arm. |
| Evidence status | Earlier studies suggest berberine and DHB supplements may improve glycemic markers and GLP-1 in prediabetes and diabetes populations, but published evidence remains limited and further research is needed to confirm these effects in people with prediabetes. | Placebo does not change glycemic or hormone markers. Use in the trial enables assessment of DHB effect versus no active treatment. |
| Important limitations | Effects of DHB in prediabetes are not well-established; studies to date have been small, with limited data on long-term safety or sustained glycemic benefit. Differences between product formulations and dosing may affect outcomes. | Placebo arms cannot provide information about active therapies or real-world care. No glycemic benefit is expected. Comparison to placebo may limit generalizability beyond trial setting. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - 6 weeks
Participants receive either Dihydroberberine (DHB) 400 mg daily or placebo capsules daily for 6 weeks to evaluate effects on glycemic control, appetite, and mood.
Multiple visits including baseline and end of treatment assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jessica M Moon, Kayla M Ratliff, Anthony M Hagele...
https://pubmed.ncbi.nlm.nih.gov/35010998/Antarmayee Panigrahi, Susant Mohanty
https://pubmed.ncbi.nlm.nih.gov/37679692/Nanjing Nutrabuilding Bio-tech Co., Ltd.
Lead Sponsor
Biofortis, Merieux NutriSciences
Collaborating Sponsor